Tyrosine Kinase Inhibitors and Male Reproductive Health

Joris J Ramstein1, Katy K Tsai2, James F Smith3,4,5

  • 1UCSF/UCB Joint Medical Program, University of California, San Francisco, San Francisco, California, USA.

Insights

Tyrosine kinase inhibitors (TKIs) can impact male fertility. This study explores the potential for TKIs to harm sperm production and function, addressing a critical knowledge gap for cancer patients desiring children.

Area of Science:

  • Oncology
  • Reproductive Biology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) are increasingly used cancer therapies.
  • The impact of TKIs on male reproductive health is largely unknown.
  • Men undergoing TKI treatment often wish to have children.

Purpose of the Study:

  • To investigate the potential for TKI medications to cause reproductive harm in men.
  • To explore the effects of TKIs on sperm parameters and spermatogenesis.

Main Methods:

  • Review of TKI mechanisms of action.
  • Analysis of potential pathways for reproductive toxicity.

Main Results:

  • TKIs target cellular signaling pathways crucial for various functions.
  • The mechanism of action suggests a potential for interference with spermatogenesis.
  • Impairment of sperm functional properties is a possible consequence.

Conclusions:

  • TKIs may pose a risk to male fertility.
  • Further research is needed to quantify the reproductive risks associated with TKI use.
  • This information is vital for cancer patients considering fertility preservation.

Related Concept Videos

Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
609
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Spermatogenesis01:41

Spermatogenesis

Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...
123.9K
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
2.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45